RT Journal Article
T1 E-cadherin expression is associated with somatostatin analogue response in acromegaly.
A1 Venegas-Moreno, Eva
A1 Flores-Martinez, Alvaro
A1 Dios, Elena
A1 Vazquez-Borrego, Mari C
A1 Ibañez-Costa, Alejandro
A1 Madrazo-Atutxa, Ainara
A1 Japon, Miguel A
A1 Castaño, Justo P
A1 Luque, Raul M
A1 Cano, David A
A1 Soto-Moreno, Alfonso
K1 E-cadherin
K1 Acromegaly
K1 Pituitary tumour
K1 Somatostatin analogues
K1 Somatostatin receptor
AB Acromegaly is a rare disease resulting from hypersecretion of growth hormone (GH) and insulin-like growth factor 1 (IGF1) typically caused by pituitary adenomas, which is associated with increased mortality and morbidity. Somatostatin analogues (SSAs) represent the primary medical therapy for acromegaly and are currently used as first-line treatment or as second-line therapy after unsuccessful pituitary surgery. However, a considerable proportion of patients do not adequately respond to SSAs treatment, and therefore, there is an urgent need to identify biomarkers predictors of response to SSAs. The aim of this study was to examine E-cadherin expression by immunohistochemistry in fifty-five GH-producing pituitary tumours and determine the potential association with response to SSAs as well as other clinical and histopathological features. Acromegaly patients with tumours expressing low E-cadherin levels exhibit a worse response to SSAs. E-cadherin levels are associated with GH-producing tumour histological subtypes. Our results indicate that the immunohistochemical detection of E-cadherin might be useful in categorizing acromegaly patients based on the response to SSAs.
PB Wiley
YR 2018
FD 2018-07-20
LK http://hdl.handle.net/10668/13671
UL http://hdl.handle.net/10668/13671
LA en
NO Venegas-Moreno E, Flores-Martinez A, Dios E, Vazquez-Borrego MC, Ibañez-Costa A, Madrazo-Atutxa A, et al. E-cadherin expression is associated with somatostatin analogue response in acromegaly. J Cell Mol Med. 2019 May;23(5):3088-3096
DS RISalud
RD Apr 8, 2025